Literature DB >> 14972369

State-related changes in cerebral white matter may underlie psychosis exacerbation.

James Christensen1, Jennifer Holcomb, David L Garver.   

Abstract

Previous reports have described accelerated loss of cerebral white matter in schizophrenia. Others have reported changes of ventricle volumes in schizophrenic patients, with greatest increases following remission of psychotic symptoms. In this study changes in cerebral white matter volumes and psychotic symptoms were measured in 16 recently decompensated schizophrenic patients from neuroleptic-free baseline to 4 weeks later during treatment with antipsychotics. Serial white matter assessments were also performed in eight controls at similar intervals. Thirteen of 16 patients showed reduction of psychotic symptoms (reduction of SAPS scores by 24.4+/-12.6) during treatment. Three patients failed to respond (increase of SAPS scores by 15.7+/-13.8). Serial volumetric studies of cerebral white matter during the 4-week period showed a decrease of white matter volume in the responders by 8.2+/-8.2 cm(3) (P=0.003). Patients who failed to respond showed a non-significant increase in white matter during the same period by 11.4+/-11.7 cm(3). Absolute and percentage changes change in white matter volumes during the 4-week period were positively correlated with changes in SAPS scores (both P<0.01). Cerebral white matter, composed of myelin-containing oligodendrocytes, is highly sensitive to excitotoxicity. Swelling of myelin and of white matter, associated interference with the speed of neurotransmission through myelinated axons, and dyssynchrony of information processing by subcortical and cortical networks may be associated with psychosis exacerbation. Partial remission of symptoms may mark temporary reduction of an active, toxic process that interferes with information processing.

Entities:  

Mesh:

Year:  2004        PMID: 14972369     DOI: 10.1016/j.pscychresns.2003.08.002

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  18 in total

1.  White matter volume abnormalities and associations with symptomatology in schizophrenia.

Authors:  Nikolaos Makris; Larry J Seidman; Todd Ahern; David N Kennedy; Verne S Caviness; Ming T Tsuang; Jill M Goldstein
Journal:  Psychiatry Res       Date:  2010-06-09       Impact factor: 3.222

2.  Evidence for white matter abnormalities in schizophrenia.

Authors:  Marek Kubicki; Robert W McCarley; Martha E Shenton
Journal:  Curr Opin Psychiatry       Date:  2005-03       Impact factor: 4.741

3.  Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.

Authors:  Philip R Szeszko; Katherine L Narr; Owen R Phillips; Joanne McCormack; Serge Sevy; Handan Gunduz-Bruce; John M Kane; Robert M Bilder; Delbert G Robinson
Journal:  Schizophr Bull       Date:  2010-11-17       Impact factor: 9.306

4.  ADC changes in schizophrenia: a diffusion-weighted imaging study.

Authors:  Igor Nenadic; Gerd Wagner; Daniel Güllmar; Claudia Schachtzabel; Katrin von Consbruch; Sabine Köhler; Kathrin Koch; Martin Roebel; C Christoph Schultz; Jürgen R Reichenbach; Heinrich Sauer; Ralf G M Schlösser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-09-26       Impact factor: 5.270

5.  Anosognosia in schizophrenia: hidden in plain sight.

Authors:  Douglas S Lehrer; Jennifer Lorenz
Journal:  Innov Clin Neurosci       Date:  2014-05

Review 6.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 7.  In vivo imaging of neuroinflammation in schizophrenia.

Authors:  Ofer Pasternak; Marek Kubicki; Martha E Shenton
Journal:  Schizophr Res       Date:  2015-06-03       Impact factor: 4.939

8.  Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients.

Authors:  Daniel Mamah; Michael P Harms; Lei Wang; Deanna Barch; Paul Thompson; Jaeyun Kim; Michael I Miller; John G Csernansky
Journal:  Biol Psychiatry       Date:  2008-03-04       Impact factor: 13.382

9.  Diffusion tractography of the fornix in schizophrenia.

Authors:  J Fitzsimmons; M Kubicki; K Smith; G Bushell; R San Jose Estepar; C-F Westin; P G Nestor; M A Niznikiewicz; R Kikinis; R W McCarley; M E Shenton
Journal:  Schizophr Res       Date:  2008-11-30       Impact factor: 4.939

10.  Temporal lobe volume in bipolar disorder: relationship with diagnosis and antipsychotic medication use.

Authors:  Lindsay D Jones; Martha E Payne; Denise F Messer; John L Beyer; James R MacFall; K Ranga R Krishnan; Warren D Taylor
Journal:  J Affect Disord       Date:  2008-08-08       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.